메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
PurposeTo evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbanceand relieving cancer pain. Materials and MethodsOne hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleepdisturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previousopioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug waspermitted at the investigator’s discretion. Pain intensity, number of breakthrough painepisodes, and quality of sleep were evaluated. ResultsA total of 120 patients received at least one dose of HM-OROS; 74 of them completed thefinal assessment. Compared to the previous opioids, HM-OROS reduced the average painNRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbanceNRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53times (p < 0.001), and immediate-release opioids use for the management of breakthroughpain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed thetreatment, 83.7% indicated that they preferred HM-OROS to the previous medication. Theadverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. ConclusionHM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. TheAEs were manageable.

목차

등록된 정보가 없습니다.

참고문헌 (23)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0